Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma

Schmid, Hans-Peter; Morant, Rudolf; Bernhard, Jürg; Maibach, Rudolf; Swiss Group for Clinical Cancer Research (SAKK), (2003). Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma. European urology, 43(1), pp. 28-30. Amsterdam: Elsevier 10.1016/S0302-2838(02)00539-0

Full text not available from this repository. (Request a copy)

In hormone refractory prostatic carcinoma (HRPCa), the majority of patients have bone metastases only, which are by definition non-measurable. This makes objective evaluation of chemotherapeutic agents difficult. Prostate specific antigen (PSA) as a dynamic model was analyzed as potential auxiliary end point in HRPCa.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Bernhard, Jürg

ISSN:

0302-2838

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:24

Last Modified:

17 Mar 2015 22:51

Publisher DOI:

10.1016/S0302-2838(02)00539-0

PubMed ID:

12507540

Web of Science ID:

000180876000005

URI:

https://boris.unibe.ch/id/eprint/37818 (FactScience: 211451)

Actions (login required)

Edit item Edit item
Provide Feedback